Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study

DOI: https://doi.org/10.1038/s41416-019-0462-1

Full-Text   Cite this paper   Add to My Lib

Abstract:

This subgroup analysis of a phase 3 study compares outcomes for eribulin versus dacarbazine in patients with leiomyosarcoma

Full-Text